↓ Skip to main content

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

Overview of attention for article published in Investigational New Drugs, April 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

patent
34 patents

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
32 Mendeley
Title
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
Published in
Investigational New Drugs, April 2013
DOI 10.1007/s10637-013-9963-6
Pubmed ID
Authors

S. Tjulandin, V. Moiseyenko, V. Semiglazov, G. Manikhas, M. Learoyd, A. Saunders, M. Stuart, U. Keilholz

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 28%
Researcher 6 19%
Student > Master 3 9%
Other 2 6%
Student > Bachelor 2 6%
Other 4 13%
Unknown 6 19%
Readers by discipline Count As %
Medicine and Dentistry 7 22%
Biochemistry, Genetics and Molecular Biology 5 16%
Pharmacology, Toxicology and Pharmaceutical Science 4 13%
Agricultural and Biological Sciences 4 13%
Chemistry 2 6%
Other 3 9%
Unknown 7 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2022.
All research outputs
#4,823,325
of 23,269,984 outputs
Outputs from Investigational New Drugs
#171
of 1,186 outputs
Outputs of similar age
#36,621
of 176,397 outputs
Outputs of similar age from Investigational New Drugs
#3
of 7 outputs
Altmetric has tracked 23,269,984 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,186 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,397 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.